GlassScriptPhysician profile
Steven Frederick Hill
NPI 1104875962
$1,660.74
in general payments reported to CMS, 2019-2025
15 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.83 · 2020: $49.77 · 2021: $336 · 2022: $348 · 2023: $393 · 2024: $320 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $715.13 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $261.52 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $160.36 | 2020-2024 | Andexxa, Farxiga, Breztri |
| Lilly USA, LLC | $114.03 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.71 | 2021-2024 | Jardiance |
| Abbvie INC. | $71.04 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $68.46 | 2021 | |
| Amgen INC. | $46.70 | 2019-2023 | Otezla, Repatha |
| Dexcom, INC. | $27.34 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $26.84 | 2022-2023 | |
| Novo Nordisk INC | $23.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.39 | 2024 | Voquezna |
| Amarin Pharma, INC. | $18.19 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.